RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score

Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview

(2017) Alvaro Arjona-Sánchez et al.   World Journal of Gastrointestinal Oncology

RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases

(2017) Kristoffer W. Brudvik et al.   ANNALS OF SURGERY

Clinicopathological Parameters in Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Metastases

(2016) Riom Kwakman et al.   ANNALS OF SURGERY

Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC

(2016) Geert A. Simkens et al.   ANNALS OF SURGICAL ONCOLOGY

“Assessment of RIFLE and AKIN criteria to define acute renal dysfunction for HIPEC procedures for ovarian and non ovarian peritoneal malignances”

(2016) A. Arjona-Sánchez et al.   EJSO

Meta-analysis ofKRASmutations and survival after resection of colorectal liver metastases

(2015) K. W. Brudvik et al.   BRITISH JOURNAL OF SURGERY

The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis

(2014) Jesus Esquivel et al.   ANNALS OF SURGICAL ONCOLOGY

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone

(2014) R Mirnezami et al.   BRITISH JOURNAL OF CANCER

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

(2014) S. Venderbosch et al.   CLINICAL CANCER RESEARCH

The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

(2014) Arancha Prada-Villaverde et al.   JOURNAL OF SURGICAL ONCOLOGY

RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

(2013) Jean-Nicolas Vauthey et al.   ANNALS OF SURGERY

The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study

(2013) D. Hompes et al.   JOURNAL OF SURGICAL ONCOLOGY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient Selection for Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis Using Serum Tumor Markers

(2012) Peter H. Cashin et al.   ANNALS OF SURGERY

Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis

(2010) Jan Franko et al.   CANCER

Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O.

(2010) F. Cavaliere et al.   EJSO

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis

(2008) Joerg O.W. Pelz et al.   JOURNAL OF SURGICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE